0000885590-13-000042.txt : 20130604 0000885590-13-000042.hdr.sgml : 20130604 20130604183431 ACCESSION NUMBER: 0000885590-13-000042 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20130531 FILED AS OF DATE: 20130604 DATE AS OF CHANGE: 20130604 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Valeant Pharmaceuticals International, Inc. CENTRAL INDEX KEY: 0000885590 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: A6 FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 4787 LEVY STREET STREET 2: MONTREAL CITY: QUEBEC STATE: A8 ZIP: H4R 2P9 BUSINESS PHONE: 514-744-6792 MAIL ADDRESS: STREET 1: 4787 LEVY STREET STREET 2: MONTREAL CITY: QUEBEC STATE: A8 ZIP: H4R 2P9 FORMER COMPANY: FORMER CONFORMED NAME: BIOVAIL Corp DATE OF NAME CHANGE: 20100416 FORMER COMPANY: FORMER CONFORMED NAME: BIOVAIL CORP INTERNATIONAL DATE OF NAME CHANGE: 19960522 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Hall Susan CENTRAL INDEX KEY: 0001542052 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-14956 FILM NUMBER: 13892707 MAIL ADDRESS: STREET 1: VALEANT PHARMACEUTICALS INTERNATIONAL STREET 2: 7150 MISSISSAUGA ROAD CITY: MISSISSAUGA STATE: A6 ZIP: L5N 8M5 4 1 primary_doc.xml PRIMARY DOCUMENT X0306 4 2013-05-31 0 0000885590 Valeant Pharmaceuticals International, Inc. VRX 0001542052 Hall Susan 2150 ST. ELZEAR BLVD. WEST LAVAL A8 H7L 4A8 QUEBEC, CANADA 0 1 0 0 Global Head of R&D Common Stock, no par values 2013-05-31 4 M 0 20694 0 A 34118 D Common Stock, no par values 2013-05-31 4 F 0 9203 0 D 24915 D Restricted Share Units 0 2013-05-31 4 M 0 20694 0 A Common Stock 20694 20694 D This represents a second payout of common shares issued upon the accelerated vesting of performance-based RSUs ("PSUs") that were previously reported on the original Form 4. The initial grant was reported to vest based on total shareholder return (TSR) between a price of $26.51 starting on September 28, 2010 and the average stock price for the prior 20 trading days as of three measurement dates: 25% would vest on June 28, 2013, 50% on September 28, 2013 and 25% on December 28, 2013. Unit vesting is contingent on TSR performance between 15% and 45% into between one and three shares of common stock, respectively, with early vesting possible at higher TSR levels. Additional common shares pursuant to this award of PSUs may be earned upon the future achievement of TSR performance targets. This number represents common shares purchased by the officer, common shares received upon settlement and/or exercise of previously granted equity awards, as well as other outstanding equity awards that were previously reported in Table 1. This number represents common shares withheld to satisfy the tax withholding obligations due upon vesting of Performance Share Units. by: Nicholas Zanoni for Sue Hall 2013-06-04